| International Journal of Nuclear Medicine Research (Special Issue - 2017) | |
| Continued Availability of the Tungsten-188/Rhenium-188 Generator to Enhance Therapeutic Utility of 188Re |  |
| Pages 3-15 F.F. (Russ) Knapp DOI: http://dx.doi.org/10.15379/2408-9788.2017.02 Published: 31 July 2017 |
|
| Abstract | |
| Rhenium-188 (188Re) is a high energy beta-emitting radioisotope of widespread interest for use in nuclear medicine, oncology and other therapeutic applications. High energy beta emission (16.9 hour half-life) with Emax 2.12 MeV and gamma emission at 155 keV (15 %) are key factors for effective therapy and imaging for tissue kinetics and dosimetry evaluation. Moreover, on-demand availability of 188Re in a highly reproducible manner from the 188W/188Re generator system is an important capability for installation in a hospital-based or a central radiopharmacy for cost effective availability of no-carrier-added (NCA) 188Re. Because of the long 69.7 day half-life of the188W generator parent, the use of well-established post 188Re elution specific volume concentration technology allow generators to have a useful/predictable operational shelf-life of a few months. This paper provides a holistic review of the development, availability and use of the 188W/188Re generator prototypes. |
|
| Keywords | |
| Beta emitters, bolus concentration, radionuclide generator, radionuclide therapy, rhenium-188, tungsten-188. | |
 |
|